These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11729538)

  • 1. Outcome comparison of patients receiving oral or depot neuroleptic medication.
    Varner RV; Hays JR; Wagner AL; Averill P
    Psychol Rep; 2001 Aug; 89(1):169-74. PubMed ID: 11729538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A loading-dose strategy for converting from oral to depot haloperidol.
    Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D
    Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
    Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M
    Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ; Kissling W
    Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract]   [Full Text] [Related]  

  • 8. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
    Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.
    Weiden P; Rapkin B; Zygmunt A; Mott T; Goldman D; Frances A
    Psychiatr Serv; 1995 Oct; 46(10):1049-54. PubMed ID: 8829787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 13. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
    Tuninger E; Levander S
    Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
    Lim HK; Kim JJ; Pae CU; Lee CU; Lee C; Paik IH
    Neuropsychobiology; 2010; 62(2):81-6. PubMed ID: 20523078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy.
    arap Mengech HN; Wazome EG
    East Afr Med J; 1984 Jun; 61(6):435-8. PubMed ID: 6152736
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.